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Abstract
Chlamydia trachomatis is the most common sexually transmitted organism in industrialized countries. Nucleic acid ampliﬁcation testing,
using non-invasively collected specimens, is considered to be the method of choice for diagnosis of chlamydial infections of the urethra
and the lower genital tract. Serological testing has the potential to circumvent the problem of specimen sampling in invasive C. trachoma-
tis infections of the upper genital tract. However, only a few deﬁned chlamydial antigens have been used in a standardized diagnostic
assay format. In this study, we used serological two-dimensional proteomic analysis to broaden the spectrum of diagnostically relevant
C. trachomatis proteins. The genes encoding an assortment of already known chlamydial antigens, as well as immunogenic proteins
that have not been described before, were cloned, and the recombinant proteins were puriﬁed in order to compare their diagnostic
usefulness in parallel with a newly developed line immunoassay. With 189 sera collected from patients with and without C. trachomatis
infection, recombinant major outer membrane protein (MOMP), chlamydial protease-like activity factor (CPAF), outer membrane
protein 2 (OMP2), translocated actin-recruiting protein, and polymorphic membrane protein D (PmpD) showed the highest level of
diagnostic sensitivity and speciﬁcity. In patients suffering from ascending and invasive C. trachomatis infections, such as pelvic inﬂamma-
tory disease and lymphogranuloma venereum, the sensitivity reached with these proteins ranged between 71% (PmpD) and 94%
(OMP2), and the speciﬁcity ranged between 82% (PmpD) and 100% (MOMP and OMP2). Recombinant thio-speciﬁc antioxidant peroxi-
dase, ribosomal protein S1 (RpsA) and hypothetical protein 17 showed lower sensitivity but comparably high speciﬁcity, ranging from
94% to 100%. The novel line immunoassay based on deﬁned recombinant antigens has promise for improved serodiagnosis in severe
and invasive C. trachomatis infections.
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Introduction
The Chlamydia trachomatis serovars D–K are among the most
common sexually transmitted bacterial organisms in industri-
alized countries, and typically cause non-gonococcal urethri-
tis in men and cervicitis in women. However, many of these
infections are asymptomatic and remain undetected, resulting
in ascending invasive infections such as salpingitis, adnexitis
and pelvic inﬂammatory disease (PID) in women [1]. Salpingi-
tis may lead to tubal scarring and consequent reproductive
complications, such as tubal-factor infertility and ectopic
pregnancy [2,3]. The C. trachomatis serovars L1–L3, including
the newly identiﬁed variant L2b, cause lymphogranuloma ven-
ereum (LGV), a systemic sexually transmitted disease that
has re-emerged in industrialized countries, especially among
men who have sex with men [4,5].
Direct detection of C. trachomatis by nucleic acid ampliﬁca-
tion testing, using non-invasively collected specimens such as
ﬁrst-void urine and vulvovaginal swab specimens, is consid-
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ered to be the method of choice for diagnosis of chlamydial
infections of the urethra and the lower genital tract [6–8].
However, diagnosis of C. trachomatis infections of the upper
genital tract may require invasive specimen sampling, such as
needle aspiration of the affected fallopian tube in women
with salpingitis [9]. Serological testing may overcome the
problem of invasive specimen sampling, as both ascending
infection of the female upper genital tract and LGV can lead
to high serum titres of anti-chlamydial antibodies [10].
The microimmunoﬂuorescence (MIF) test developed by
Wang and Grayston [11] is still considered to be the method
of choice for serodiagnosis of chlamydial infections. Problems
with the MIF assay format include poor standardization,
subjective reading of titres, and a labour-intensive assay. How-
ever, until now, only a few deﬁned chlamydial antigens have
been used in a standardized diagnostic assay format [12,13].
In order to broaden the spectrum of immunogens, a pro-
teomic approach including two-dimensional PAGE and subse-
quent analysis of immunoreactive proteins by mass
spectrometry (MS) was used. We identiﬁed not only already
known chlamydial immunogens, such as major outer
membrane protein (MOMP), cysteine-rich outer membrane
protein 2 (OMP2), chlamydial heat shock protein 60
(cHSP60), translocated actin-recruiting protein (TARP), and
polymorphic membrane protein D (PmpD), but also antigens
that have not been described before, such as thio-speciﬁc
antioxidant peroxidase (TSAP), ribosomal protein S1 (RpsA)
and hypothetical protein 17 (HP17). The immunogenic
proteins were recombinantly synthesized, puriﬁed, and tested
in a line immunoassay for systematic evaluation of their diag-
nostic value, focusing on patients with severe and invasive
C. trachomatis infections.
Materials and Methods
Organisms and cultivation
The reference strain C. trachomatis serovar D/UW-3/Cx
(ATCC-VR885) was used for puriﬁcation of chlamydial
elementary bodies and preparation of chromosomal DNA.
The strain was cultured in cycloheximide-treated HeLa 229
cell monolayers (ATCC; CCL 2.1) according to standard
procedures [14].
Human sera
Sera were obtained from patients attending the university
hospital of Ulm after informed consent and approval by the
local ethical committee had been obtained.
Sera from 13 patients presenting at the university hospital
clinic of gynaecology and obstetrics with typical clinical signs
of ascending invasive C. trachomatis infections of the upper
genital tract, such as salpingitis, adnexitis, and PID, were
selected for identiﬁcation of immunoreactive C. trachomatis
proteins by serological two-dimensional proteomic analysis.
C. trachomatis infections were conﬁrmed by the detection of
C. trachomatis-speciﬁc nucleic acids, using the commercially
available AMPLICOR PCR assay (Roche Diagnostics, Mann-
heim, Germany) and/or by detection of C. trachomatis-speciﬁc
IgM and/or elevated IgG antibodies using a MIF assay (MRL
Diagnostics, Cypress, CA, USA). Subsequently, 189 sera
were used for evaluation of recombinant proteins that were
identiﬁed as chlamydial antigens by serological two-dimen-
sional proteomic analysis. They included sera that were col-
lected from 64 patients with various clinical manifestations of
TABLE 1. Characteristics of human sera used in this study.
(a) Sera from patients with Chlamydia trachomatis (C.tr.)
infection. (b) Control group
(a)
PCR-C.tr. MIF-C.tr.
Female upper genital
tract infections
Positive 20 31
Negative 4 2
ND 9 0
Total 33 33
LGV Positive 11 11
Negative 0 0
ND 0 0
Total 11 11
Rare manifestations Positive 4 4
Negative 0 0
ND 0 0
Total 4 4
Infection during pregnancy Positive 10 7
Negative 0 3
ND 0 0
Total 10 10
Urethritis Positive 6 3
Negative 0 3
ND 0 0
Total 6 6
Overall total 64 64
(b)
MIF titre C.pn. No. of sera
<32 59
32 10
64 10
128 16
256 16
‡512 14
Total 125
ND, not done.
Sera were collected from 64 patients suffering from various clinical manifesta-
tions of C. trachomatis infection: female upper genital tract infections, including
salpingitis, adnexitis, and pelvic inﬂammatory disease (33 sera), lymphogranuloma
venereum (LGV) (11 sera), rare manifestations such as epididymitis, uveitis, and
reactive arthritis (four sera), infection during pregnancy (ten sera), and urethritis
(six sera). C. trachomatis infections were detected by PCR and/or serology using
a commercially available microimmunoﬂuorescence (MIF) assay (see Materials
and Methods). MIF positivity was deﬁned as detection of IgM antibodies and/or
elevated IgG antibodies (>1 : 128).
Sera (n = 125) were collected from age-matched and sex-matched hospital
patients and healthy blood donors without clinical and serological signs of C. tra-
chomatis infection, as described in Materials and Methods. Table 1b shows the
serostatus of the control sera with respect to Chlamydia pneumoniae (C.pn.)-
speciﬁc IgG titres as determined by MIF assay.
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C. trachomatis infection, including female upper genital tract
infection (33 sera), urethritis (six sera), LGV (11 sera), rare
manifestations such as epididymitis, uveitis and reactive
arthritis (four sera), and infection during pregnancy (ten
sera). C. trachomatis infections were identiﬁed as described
above (Table 1a). The control group (n = 125) comprised
101 sera from age-matched and sex-matched hospital
patients without clinical or serological signs of C. trachomatis
infection and 24 serum samples of healthy blood donors.
Sixty-six (53%) sera of the control group did show IgG anti-
bodies against C. pneumoniae at titres in the range of 32 to
512, as determined by MIF (MRL Diagnostics, Cypress, CA,
USA) (Table 1b).
Two-dimensional immunoblot analysis and protein
identiﬁcation
Approximately 30 lg of chlamydial protein preparations
were applied to Ready IPG Strips, pH 3–10, 11 cm (BioRad,
Hercules, CA, USA), which were used according to the
manufacturer’s instructions. After isoelectric focusing, chla-
mydial proteins were separated by SDS-PAGE in a 10%
polyacrylamide gel system. SDS-PAGE gels were blotted
onto Immobilon polyvinylidene diﬂuoride membranes
(Millipore, Billerica, MA, USA) for immunoblot analysis,
as described previously [15], or they were stained with
Coomassie Brilliant Blue G (Serva, Heidelberg, Germany)
for isolation and identiﬁcation of proteins in single spots by
MS-based assays. Reactive spots detected by immunoblot
analysis were correlated with Coomassie-stained proteins
using Delta2D software (DECODON, Greifswald, Ger-
many). The spots were excised from dried gels, and the
proteins were subjected to sequence analysis. Protein iden-
tiﬁcation using nano-liquid chromatography electrospray ion-
ization MS/MS was performed by Proteome Factory AG
(Berlin, Germany) [16].
Gene cloning and expression of recombinant proteins
Cloning and expression of the recombinant chlamydial pro-
teins, namely MOMP, OMP2, cHSP60, TARP, TSAP, RpsA,
HP17, and chlamydial protease-like activity factor (CPAF),
was performed as described previously [17,18]. The recom-
binant antigens were expressed as full-length proteins, but
without the sequences coding for putative signal peptides in
Escherichia coli, and brought to high purity using standard
chromatographic methods. In addition, we evaluated, in our
newly developed line immunoassay, two recombinant
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FIG. 1. Two-dimensional immunoblots of sera
collected from patients with invasive Chlamydia
trachomatis infections of the female upper
genital tract. Representative two-dimensional
immunoblots obtained using sera from
patients (n = 13) with clinical signs of ascend-
ing or invasive C. trachomatis infections of the
female upper genital tract, such as salpingitis,
adnexitis, and pelvic inﬂammatory disease PID.
Letters A, E, F and J represent different
patients and refer to Table 2. Spots were anal-
ysed by mass spectrometry-based methods, as
described in Materials and Methods. Spots
found to be major immunogens are marked by
protein names. cHSP, chlamydial heat shock
protein; IEF, isoelectric focusing; MOMP,
major outer membrane protein; OMP2, outer
membrane protein 2; PmpD, polymorphic
membrane protein D; TARP, translocated
actin-recruiting protein.
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fragments of PmpD, PmpD-2 and PmpD-3, which correlate
with the middle and C-terminal portions of the PmpD
passenger domain, respectively [19].
Production and processing of nitrocellulose strips (line
immunoassay)
Individual dilutions of puriﬁed recombinant antigens were
applied directly onto nitrocellulose membranes in separate
lanes. The reactivity of 1 : 100 dilutions of serum antibod-
ies against the recombinant antigens was detected with
peroxidase-labelled anti-human IgG antibody and the use of
tetramethylbenzidine. Controls were used as described
previously [17]. An OpticPro S28 scanner (Plustek, Nor-
derstedt, Germany) and RecomScan software (MIKROGEN,
Neuried, Germany) were used according to the instruction
manuals.
Statistical analysis
The McNemar test (Analyse-it for Microsoft Excel
Version 1.71) was used for statistical evaluation. Statistical
signiﬁcance was accepted at p £0.05.
Results
Detection of chlamydial antigenic proteins using two-
dimensional immunoblots
Representative examples of two-dimensional immunoblots
obtained using 13 sera of patients with severe C. trachomatis
infection of the female upper genital tract are shown in
Fig. 1. The major immunoreactivities, including MOMP,
cHSP60, cHSP70, and PmpD, are characterized by prominent
and large spots that show a pattern similar to all patient sera
(for gene names see Table 2). In contrast, variable reactivity
with frequencies ranging from 15% to 92% was observed for
a panel of spots identiﬁed as OMP2, adenylate cyclase-like
protein, EF-Tu, TARP, RpsA, ATP-dependent Clp protease
proteolytic subunit 1, TSAP, RplA, and HP17 (Table 2). As
expected, CPAF could not be detected by serological two-
dimensional analysis of C. trachomatis, as this protein requires
chlamydial replication for its production and does not pre-
exist in the chlamydial elementary bodies [20] that were
used for two-dimensional immunoblot analysis.
TABLE 2. Overview of two-dimensional proteomic analysis of sera from patients with invasive Chlamydia trachomatis infections
of the female upper genital tract
Gene name (protein name)
Locus name
Calculated
molecular
mass (kDa)/pI A B C D E F G H I J K L M Frequency
ompA (MOMP)
CT_681
42.4/4.86 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ ++ ++ 13/13 (100%)
groEL (cHSP60)
CT_110
58.1/4.99 +++ ++ +++ +++ +++ +++ +++ +++ (+) +++ + (+) +++ 13/13 (100%)
dnaK (cHSP70)
CT_396
70.8/4.75 ++ ++ + + ++ + +++ +++ + +++ + (+) + 13/13 (100%)
omp2 (OMP2)
CT_443
59.3/7.23 ) +++ + + +++ + +++ ++ ++ ++ + + ++ 12/13 (92.3%)
tuf (elongation factor,
thermo-unstable, EF-Tu)
CT_322
43.3 / 5.22 + +++ +++ + ) + +++ + ) +++ ) (+) ) 9/13 (69.2%)
rpsA (ribosomal protein S1, RpsA)
CT_098
63.6/4.92 ++ ) ) ) + + ) ) + ) + ) ) 5/13 (38.5%)
pmpD (PmpD)
CT_812
160.7/4.47 ++ ++ ++ + ++ ++ +++ (+) + ++ + (+) (+) 13/13 (100%)
(adenylate cyclase-like protein)
CT_664
89.6/4.24 + + + + ) + ++ (+) ++ (+) + (+) ) 11/13 (84.6%)
tarP (TARP)
CT_456
102.1/4.01 + ) ) ) + ) + (+) ++ (+) ++ (+) ) 8/13 (61.5%)
clpP1 (ATP-dependent Clp protease
proteolytic subunit 1, ClpP1)
CT_431
21.1/5.28 (+) ) ) ) ) + (+) ) ) (+) ) ) ) 4/13 (30.8%)
ahpC (thio-speciﬁc antioxidant
peroxidase, AhpC)
CT_603
21.7/4.48 ) + + + ) (+) ) ) ) ) ) ) ) 4/13 (30.8%)
rplA (ribosomal protein L1, RplA)
CT_318
24.7/9.43 + + ) ) ) ) ) ) ) ) ) ) ) 2/13 (15.4%)
(hypothetical protein, HP17)
CT_017
47.8/7.49 + + + ) ) ) (+) (+) + ) ) ) ) 6/13 (46.1%)
cHSP, chlamydial heat shock protein; MOMP, major outer membrane protein; OMP2, outer membrane protein 2; PmpD, polymorphic membrane protein D; TARP, translo-
cated actin-recruiting protein.
The letters A–M represent serum samples from different patients with invasive C. trachomatis infections of the female upper genital tract. The corresponding columns describe
the different recognition patterns of individual sera; 15 identiﬁed chlamydial antigens are listed in rows. The signal intensities of reactive protein spots are presented semi-
quantitatively: ), negative; (+), very weak; +, weak; ++, moderate; +++, strong. Column 2 gives the calculated molecular mass and the isoelectric point (pI) of the identiﬁed
proteins.
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Evaluation of identiﬁed chlamydial antigens using a line
immunoassay
The reactivity of already known chlamydial antigens such as
MOMP, cHSP60, OMP2, CPAF, PmpD and an assortment of
another four immunogenic proteins (TARP, RpsA, TSAP and
HP17), which were detected by serological two-dimensional
proteomic analysis, was evaluated using a line immunoassay.
This arrangement allowed the analysis of sera by means of
ten different chlamydial antigens in one single experiment
(Fig. 2). Respective line assay results for sera representing
patients with localized infections (urethritis), or severe or
invasive infections (PID or LGV), and results for sera col-
lected during pregnancy, are shown in Fig. 2a. Obvious differ-
ences in the reactivity of sera representing localized
(urethritis) and severe or invasive infection were observed
with respect to the recognition frequency. Sera from patients
with urethritis yielded signiﬁcantly fewer and weaker signals
than sera from patients with PCR-conﬁrmed PID or LGV
(Fig. 2a). On the basis of preliminary evaluations, a four-band
criterion was selected to indicate a positive overall line
immunoassay result. If four or more reactive bands were
considered to be positive, the test results for the group of
severe or invasive infections, which represents the target
group of this assay, had a sensitivity of 100%, a speciﬁcity of
98.4%, a positive predictive value of 93.9%, and a negative
predictive value of 100% (data not shown).
Analysis of ten serum samples collected from C. trachoma-
tis PCR-positive pregnant women resulted in heterogeneous
line immunoassay patterns showing either only a few reactive
bands (a representative example is presented in Fig. 2a,
lane 4) or in-line immunoassay patterns of four or more
reactive bands (a corresponding example is shown in Fig. 2a,
lane 3). Further investigation is needed to determine
whether these different reaction patterns reﬂect different
periods of infection.
Sera from 101 patients without any serological and clinical
signs of C. trachomatis infection and from 24 healthy blood
donors were used as negative control sera. To detect poten-
tial cross-reactivity of antigens, approximately 50% of sera
were collected from individuals with serological signs of past
C. pneumoniae infection. Comparison of the control serum
subgroups with and without C. pneumoniae-speciﬁc antibody
(5) Urethritis 
(2) LGV 
(1) PID 
Sera collected 
during pregnancy } (3) (4) 
1 
2 
3 
4 
5 
MIF-C. pn
< 32 
1:64 
1:512 
1:512 
1:128 
1:128 1 
2 
3 
4 
5 
6 
(a)
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FIG. 2. Evaluation of the line immunoassay with selected antigens. (a) Representative examples of the line assay results obtained using sera spe-
ciﬁc for pelvic inﬂammatory disease (PID) (1), lymphogranuloma venereum (LGV) (2), and urethritis (5), and sera collected during pregnancy
showing multiple reactive bands (3) and only a few reactive bands (4), respectively. (b) Representative examples (1–6) of the results obtained
using negative control sera collected from individuals showing neither clinical nor serological signs of Chlamydia trachomatis (C.tr.) infection and
the serostatus of the control sera with respect to Chlamydia pneumoniae (C.pn.)-speciﬁc IgG titres as determined by microimmunoﬂuorescence
(MIF) assay. Two control bands were applied at the upper end of the test strip: the reaction control band (Reak-Ko), which must show a reac-
tion to every serum, and the ‘Cut-off control’ for control of the colouration process and evaluation of the test strip. The intensity of the test
band provides the basis for evaluation of the antibody reactivity as positive or negative. cHSP, chlamydial heat shock protein; MOMP, major
outer membrane protein; OMP2, outer membrane protein 2; PmpD, polymorphic membrane protein D; TARP, translocated actin-recruiting pro-
tein; TSAP, thio-speciﬁc antioxidant peroxidase.
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titres revealed no signiﬁcant differences in sensitivity or
speciﬁcity of the evaluated chlamydial proteins, indicating no
relevant cross-reactivities between the C. trachomatis-speciﬁc
proteins and C. pneumoniae-speciﬁc antibodies (data not
shown). An exception was TARP, which was recognized by
11 of 66 control sera with C. pneumoniae-speciﬁc antibody
titres.
As PCR results were not available at the time of serum
collection, we cannot completely rule out the possibility that
single individuals with clinically asymptomatic infections and
without any serological response to C. trachomatis might be
included in the negative control group. However, this assay
is devised for the detection of C. trachomatis-speciﬁc antibod-
ies in symptomatic patients suffering from ascending or inva-
sive infections. Representative line immunoassays of negative
controls are shown in Fig. 2b. With reference to all 64 sera
from patients with C. trachomatis infections and 125 negative
control sera, false-positive reactivity resulting in signiﬁcantly
decreased diagnostic speciﬁcity of less than 90% was
observed only for PmpD (Table 3). All other recombinant
proteins, including MOMP, OMP2, CPAF, TARP, cHSP60,
TSAP, RpsA and HP17, showed a diagnostic speciﬁcity of
90–100%.
Recombinant MOMP, OMP2 and CPAF showed an over-
all diagnostic sensitivity of more than 80% and a speciﬁcity
of up to 100% when applied to the newly developed line
immunoassay (Table 3a). The sensitivities of these antigens
were 87% for MOMP, 90% for CPAF, and 94% for OMP2
when PCR-positive patients with severe or invasive C. tra-
chomatis infections were considered (Table 3b). The sensi-
tivities and speciﬁcities of MOMP, OMP2 and CPAF, did
not differ signiﬁcantly from each other. Two-dimensional
proteomic analysis revealed TARP to be an inducer of the
human immune response. Recombinant TARP was recog-
nized by 84% of sera from patients with PCR-conﬁrmed
PID and LGV. In these patients, the diagnostic sensitivity of
TARP did not differ signiﬁcantly (p >0.05) from that of
MOMP, which has previously been described as a major
immunogen [21]. Evaluation of PmpD comprised the com-
bined analysis of two recombinant PmpD fragments (see
Materials and Methods). The overall sensitivity and speciﬁc-
ity of PmpD in patients with invasive infections were 71%
and 82%, respectively.
This study presents the ﬁrst experimental evidence of
the immunogenicity of the C. trachomatis proteins TSAP,
RpsA and HP17. Although these antigens showed diagnostic
sensitivity that ranged from only 23% to 45%, high speciﬁcity
ranging from 94% to 100% was observed (Table 3b).
Discussion
To evaluate systematically the diagnostic potential of immuno-
reactive proteins identiﬁed by serological two-dimensional
TABLE 3. Evaluation of speciﬁcity and sensitivity of the recombinant proteins used in this study
Sensitivity
p (sensitivity as compared
with MOMP) Speciﬁcity
p (speciﬁcity as compared
with MOMP) PPV (%) NPV (%)
(a)
MOMP 83% (53/64) – 100% (0/125) – 100 92
OMP2 92% (59/64) 0.1796 100% (0/125) 1 100 96
CPAF 84% (54/64) 1 98% (2/125) 0.5 96 92
TARP 73% (47/64) 0.2101 90% (12/125) 0.0005 80 87
PmpD 70% (45/64) 0.0768 82% (23/125) <0.0001 66 84
cHSP60 61% (39/64) 0.0043 90% (12/125) 0.0005 76 82
HP17 45% (29/64) <0.0001 94% (8/125) 0.0156 78 77
RpsA 22% (14/64) <0.0001 100% (0/125) 1 100 71
TSAP 38% (24/64) <0.0001 99% (1/125) 1 96 76
(b)
MOMP 87% (27/31) – 100% (0/125) – 100 97
OMP2 94% (29/31) 0.6875 100% (0/125) 1 100 98
CPAF 90% (28/31) 1 98% (2/125) 0.5 93 98
TARP 84% (26/31) 1 90% (12/125) 0.0005 68 96
PmpD 71% (22/31) 0.1797 82% (23/125) <0.0001 49 92
cHSP60 61% (19/31) 0.0215 90% (12/125) 0.0005 61 90
HP17 42% (13/31) 0.0013 94% (8/125) 0.0156 62 87
RpsA 23% (7/31) <0.0001 100% (0/125) 1 100 84
TSAP 45% (14/31) 0.001 99% (1/125) 1 93 88
cHSP, chlamydial heat shock protein; CPAF, chlamydial protease-like activity factor; HP17, hypothetical protein 17; MOMP, major outer membrane protein; NPV, negative
predictive value; OMP2, outer membrane protein 2; PmpD, polymorphic membrane protein D; PPV, positive predictive value; RpsA, ribosomal protein S1; TARP, translocated
actin-recruiting protein; TSAP, thio-speciﬁc antioxidant peroxidase.
Sensitivities, speciﬁcities, PPVs and NPVs of recombinant proteins were calculated using (a) sera from 64 patients presenting with various clinical manifestations of Chlamydia
trachomatis infections, including local, invasive and asymptomatic infections, and (b) only sera from patients with PCR-conﬁrmed upper genital tract or invasive infections
including, salpingitis, adnexitis, pelvic inﬂammatory disease and lymphogranuloma venereum (n = 31). The absolute numbers of reactive sera from patients with C. trachomatis
infection are presented in parentheses in the sensitivity columns. The absolute numbers of reactive sera from the negative control group are presented in parentheses in the
speciﬁcity columns. p-Values refer to signiﬁcant or non-signiﬁcant differences in sensitivity and speciﬁcity in comparison with MOMP. p-Values <0.05 were considered to be
signiﬁcant.
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proteomic analysis, we developed a novel line immunoassay
that comprises ten recombinant chlamydial antigens, including
well-known antigens such as MOMP, OMP2 and cHSP60,
and newly described antigens such as PmpD, TARP, TSAP,
RpsA and HP17. In addition, recombinant CPAF was synthe-
sized and used in the assay, because this virulence-associated
protein has been described as being highly immunogenic in
humans, although it could not be detected by the two-
dimensional approach, most probably because it is not a
structural part of chlamydial elementary bodies and is
secreted into the host cell cytosol during infection [20].
We demonstrated that recombinant MOMP, CPAF,
OMP2, TARP and PmpD showed the highest overall diag-
nostic sensitivity and speciﬁcity in our patient setting. In the
subgroup of patients suffering from severe and invasive
C. trachomatis infections, such as LGV and PID, in which a
strong humoral immune response can be expected [10], the
sensitivity reached with these proteins ranged between 71%
(PmpD) and 94% (OMP2), and the speciﬁcity ranged
between 82% (PmpD) and 100% (MOMP and OMP2).
MOMP has been shown previously to be immunodominant
in C. trachomatis infections [21]. The high speciﬁcity of
OMP2 was somewhat unexpected, as this protein has been
described as a major immunogen [22] eliciting no species-
speciﬁc humoral response [23]. This discrepancy might be
due to the differences in the conformation between the
truncated fusion protein used in the study of Mygind et al.
[23] and the full-length protein applied to nitrocellulose
strips in this study.
Among the antigens newly identiﬁed by two-dimensional
immunoblot analysis, the type III secreted TARP is a promis-
ing candidate for C. trachomatis serodiagnosis, as this protein
showed a high diagnostic sensitivity of 84% that did not differ
signiﬁcantly from the sensitivities of MOMP and OMP2 in
patients with severe or invasive infections. However, more
studies are needed to clarify whether TARP shows a some-
what decreased speciﬁcity, especially in patients with Chlamydia
pneumoniae antibodies. Two recombinant fragments of PmpD,
another virulence-associated protein [24], showed a lower
sensitivity of 71%, and a speciﬁcity of 82%. Because these two
fragments form the passenger domain of PmpD, which was
previously found to be secreted into the inclusion lumen
[25,26], the results of this study demonstrate that the anti-
body response in severe C. trachomatis infection targets not
only surface-associated proteins, but also secreted and
virulence-associated proteins, similar to what has been found
for CPAF by other investigators [20,27].
RpsA, HP17 and TSAP were identiﬁed as minor immuno-
gens in C. trachomatis infection, showing diagnostic sensitivi-
ties of 23%, 42%, and 45%, respectively. However, these
proteins seem to be highly speciﬁc for C. trachomatis
infection, as their diagnostic speciﬁcity ranged from 94% to
100%. Further studies are needed to clarify whether these
proteins could play a role as supplementary antigens for diag-
nostic purposes. In general, the strong humoral response in
the subgroup of patients with severe or invasive C. trachoma-
tis infections is reﬂected by the presence of four or more
prominent bands in the line immunoassay including major
and minor antigens.
Even in the molecular diagnostics era, serological testing
could be useful in the management of certain clinical presen-
tations of C. trachomatis infection [2,28,29]. With serological
two-dimensional proteomic analysis, Sanchez-Campillo et al.
[30] ﬁrst demonstrated that it could be successfully used to
identify major immunogens in severe or invasive C. trachoma-
tis infections. Our data show that recombinant MOMP,
CPAF, OMP2, TARP and PmpD, which are considered to be
major immunogens, could be useful in the reliable serological
diagnosis of severe and invasive C. trachomatis infections.
Owing to their high speciﬁcity, minor immunogens such as
RpsA, TSAP and HP17 could serve as supplementary anti-
gens. Clearly, more studies are needed to substantiate their
diagnostic beneﬁt.
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